All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma hub is happy to present a visual abstract representing key data from a phase 1 trial (NCT02500407) evaluating the safety, efficacy and recommended phase 2 dose for Mosunetuzumab, a bispecific antibody for relapsed or refractory B-cell non-Hodgkin lymphomas. Preliminary results were previously reported in January 2020.
To download this visual abstract, click below.Download here
Preliminary results from phase I studies of CD20 × CD3 bispecific antibodies in R/R B-cell non-Hodgkin lymphoma
For patients with B-cell non-Hodgkin lymphoma (NHL) who relapse or become refractory to chemotherapy and anti-CD20 immunotherapy, there...
Risk of subsequent neoplasms following allo-HSCT with different conditioning regimens
In this study, the authors sought to investigate whether HSCT conditioning regimens of various intensities impact on the occurrence of SMNs.
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox